Merck stock price slips after FDA fast-track questions; what MRK investors watch next week
Merck & Co shares dropped 1.9% on Friday, ending the day at $108.83. That’s roughly 4% shy of their 52-week peak of $112.90 hit earlier this month.
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit
Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open.
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom
U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week.
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week
Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication.
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week
Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33.
Merck stock price slips as FDA fast-track doubts surface before MRK earnings
Shares of Merck & Co dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded.
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang
Eli Lilly shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, noted the delay signals the agency remains cautious, essentially saying: “Hold on, we’re not actually sure this product should be allowed on the market.”
Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus
Eli Lilly shares rose 0.3% to $1,036.46 on Friday morning, after touching as low as $1,019, as investors weighed an updated U.S. regulatory timeline for the company’s experimental obesity pill.
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed
Eli Lilly and Co shares slipped 3.8% in premarket trading Friday, following a wave of regulatory and legal news around its obesity drugs late last week. The stock last traded at $1,032.97.
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10
Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns raised by FDA scientists.
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10
Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez Lynch, a health-policy professor at the University of Pennsylvania, commented on the FDA’s cautious stance, saying, “Hold on, we’re not actually sure this product should be allowed on the market,” highlighting the agency’s readiness to slow fast-tracked reviews.
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push
Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment.
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names
Shares of Structure Therapeutics jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares.
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings
Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next
Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning.
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens
Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound.
Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention
NVIDIA Corporation shares barely moved Tuesday following a report that China is restricting approvals for buying the company’s H200 AI chips. The stock last dipped 0.04% to $184.87 shortly after the close, after bouncing between $183.45 and $188.08.
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms
Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration's request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy.
Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus
Nvidia shares held steady in early New York trading Tuesday after the company announced it won’t require upfront payments for its H200 AI chips. The stock ticked up just 0.03% to $184.94.
TechStock² Updates
